Last updated: February 24, 2026
What is the Drug with NDC 59651-0348?
NDC 59651-0348 corresponds to Nadofaragene Firadenovec, a gene therapy indicated for the treatment of bladder cancer, specifically non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without urinary biorhythm.
This therapy has gained regulatory approval recently, with its primary market in the US and potential expansion to other regions.
Market Overview
Target Population
- Total NMIBC Cases in the US (2022): Approximately 70,000 new cases annually.
- CIS Patients: Estimated 20-30% of NMIBC patients, translating into roughly 14,000-21,000 annual cases eligible for gene therapy.
- Refractory or BCG-unresponsive CIS: A subset of CIS, about 40-50% of CIS patients.
Competitive Landscape
| Therapy |
Approvals |
Market Share (Est.) |
Notes |
| Nadofaragene Firadenovec |
Approved |
0% (new entrant) |
First gene therapy for CIS in bladder cancer in US. |
| BCG (Bacillus Calmette-Guérin) |
Widely used |
~70% (of NMIBC) |
Standard of care, limited in refractory cases. |
| Valrubicin |
Approved |
<5% |
Salvage therapy, less effective. |
Regulatory and Reimbursement Status
- FDA: Approved (2022) for CIS unresponsive to BCG.
- Pricing (US): Listed price approximately $15,000 per dose; multi-dose regimen.
- Reimbursement: Covered by major insurers under cancer treatment protocols.
Market Penetration and Adoption Drivers
Factors Accelerating Adoption
- Unmet Need: Limited options for BCG-unresponsive CIS.
- Regulatory Approval: Validates the therapy’s market entry.
- Clinical Data: Demonstrates durable responses, boosting physician confidence.
- Pricing Strategy: Competitive with existing treatments, considering high-value positioning.
Barriers
- Limited Awareness: Among clinicians unfamiliar with gene therapy.
- Logistics: Need for specialized handling and administration.
- Cost Concerns: Payer hesitations regarding high upfront costs.
Price Projection
Current Pricing Dynamics
| Price Component |
Estimated Cost |
Notes |
| Per-dose List Price |
~$15,000 |
US list price, covering active therapy dose. |
| Complete Treatment Regimen |
~$45,000 - $60,000 |
Three doses over one year; may differ regionally. |
Future Price Trends (2023-2030)
| Year |
Expected Price Range |
Rationale |
| 2023 |
$15,000 - $18,000 |
Initial market entry with premium pricing aligned with innovation. |
| 2025 |
$12,000 - $15,000 |
Competitive pricing due to increased manufacturing efficiency and market competition. |
| 2030 |
$8,000 - $12,000 |
Potential price reductions driven by biosimilar-like competition and expanded access. |
Key Influencing Factors
- Manufacturing efficiencies will reduce costs.
- Reimbursement policies may limit maximum patient out-of-pocket costs.
- Market adoption pace influences economies of scale.
- Regional price differences will be significant, with US prices generally higher than Europe or Asia.
Revenue Forecasts (US Market)
| Year |
Estimated Patients (Refractory CIS) |
Average Price per Patient |
Estimated Revenue |
Remarks |
| 2023 |
4,000 |
$15,000 |
$60 million |
Launch year, slow uptake. |
| 2025 |
8,000 |
$15,000 |
$120 million |
Increasing clinician adoption. |
| 2030 |
12,000 |
$10,000 - $12,000 |
$120 - $144 million |
Market expansion, price reduction. |
Growth Drivers
- Rising awareness of gene therapy options.
- Broader approval for additional indications.
- Expansion into European and Asian markets with adjusted pricing.
Key Takeaways
- The initial US price per treatment is approximately $15,000, with potential to decline to below $10,000 by 2030.
- The total addressable US market is roughly $120-$144 million annually, assuming adoption grows to 12,000 patients.
- Market entry is challenged by clinician familiarity and reimbursement hurdles but benefits from high unmet medical needs.
- Price reduction strategies and expansion into international markets will influence long-term revenue potential.
FAQs
Q1: How does Nadofaragene Firadenovec compare in cost to existing therapies?
It is priced similarly to other approved bladder cancer treatments, with initial therapy costs around $15,000 per dose. The total regimen costs about $45,000 to $60,000, comparable or slightly higher than BCG or valrubicin in refractory cases.
Q2: Will prices decline over time?
Yes. As manufacturing scales, competition increases, and biosimilar-like products emerge, prices are expected to decrease, potentially to $8,000-$12,000 per course by 2030.
Q3: What factors could impact market acceptance?
Physician familiarity, logistical challenges in administration, payer policies, and clinical outcome data influence adoption speed.
Q4: Are there any international pricing differences?
Yes. European and Asian markets typically have lower pricing due to different healthcare reimbursement frameworks and price regulation policies.
Q5: What is the outlook for long-term revenue?
Revenue will depend on market penetration rates, price adjustments, indication expansion, and reimbursement policies. A conservative estimate for the US market suggests potential revenues of $100-$150 million annually by 2030.
References
-
Food and Drug Administration (FDA). (2022). FDA approves first gene therapy for bladder cancer. https://www.fda.gov
-
IQVIA. (2022). US Oncology Market Trends. IQVIA Institute.
-
EvaluatePharma. (2022). World Preview 2022: Outlook to 2027. EvaluatePharma.
-
Centers for Disease Control and Prevention (CDC). (2022). Bladder Cancer Statistics. https://www.cdc.gov
-
MarketResearch.com. (2023). Bladder Cancer Treatment Market Forecasts and Trends.
[1] Refer to regulatory FDA data and recent approvals for clinical and market insights (FDA, 2022).
